Trends in kinase drug discovery: targets, indications and inhibitor design
Trends in kinase drug discovery: targets, indications and inhibitor design
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. Twenty years on, this article analyses the landscape of approved and investigational therapies that target kinases and trends within it, including the mos...
Alternative Titles
Full title
Trends in kinase drug discovery: targets, indications and inhibitor design
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_uu_469669
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_469669
Other Identifiers
ISSN
1474-1776,1474-1784
E-ISSN
1474-1784
DOI
10.1038/s41573-021-00252-y
